COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN THE UNITED STATES

被引：2
|
作者：
Monk, Bradley [1 ]
Boer, Jennifer [2 ]
Van Hees, Frank [2 ]
Van Mens, Sophie [2 ]
Swami, Shilpi [3 ]
Muston, Dominic [4 ]
Tekin, Cumhur [4 ]
Keefe, Steve [4 ]
Monberg, Matthew [4 ]
机构：
[1] Creighton Univ, Sch Med, HonorHlth Res Inst, Div Gynecol Oncol,Univ Arizona, Phoenix, AZ USA
[2] Lumanity, Luman Heat Econ Anal Team, Utrecht, Netherlands
[3] MSD UK Ltd, Biostat & Res Decis Sci, London, England
[4] Merck & Co Inc, Rahway, NJ USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷
关键词：
D O I：
10.1136/ijgc-2022-igcs.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
29/#956
引用
收藏
页码：A38 / A38
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
    Monk, Bradley J.
    van Mens, Sophie
    Hale, Oliver
    Boer, Jennifer
    van Hees, Frank
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 85 - 98
  • [2] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, AND METASTATIC CERVICAL CANCER IN THE UNITED STATES: RESULTS FROM THE FINAL ANALYSIS OF TRIAL
    Swami, S.
    Hale, O.
    Thornton, I
    Muston, D.
    Monberg, M. J.
    Monk, B. J.
    VALUE IN HEALTH, 2023, 26 (12) : S183 - S183
  • [3] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Swami, S.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S62 - S62
  • [4] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF PD-L1 POSITIVE PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Nedzesky, J.
    Veenstra, D.
    VALUE IN HEALTH, 2022, 25 (07) : S343 - S343
  • [5] Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer
    Shi, Yang
    Chen, Jigang
    Shi, Bo
    Liu, Aihua
    GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 379 - 385
  • [6] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
    Borse, Rebekah H.
    Ramakrishnan, Karthik
    Gandhi, Jyotika
    Dhankhar, Praveen
    Chirovsky, Diana
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 954 - 965
  • [7] Pembrolizumab for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis
    Barrington, David
    Riedinger, Courtney
    Haight, Paulina
    Tubbs, Crystal
    Cohn, David
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S19 - S19
  • [8] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [9] Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
    Lin, Ying-tao
    Wang, Chang
    He, Xiao-yan
    Yao, Qi-min
    Chen, Jian
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [10] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
12345